ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: To validate the predicted tyrosine kinase activities from KSTAR, we compared the kinase activity profiles of the CML cell line K562 in response to treatment with the ABL-inhibitor dasatinib from a study by Asmussen et al., who profiled phosphopeptide abundance before treatment, at the time of drug washout (EOE), and 3 and 6 h post drug washout (HDP3 and HDP6, respectively)34.